159 related articles for article (PubMed ID: 33466794)
1. PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Crosta S; Boldorini R; Bono F; Brambilla V; Dainese E; Fusco N; Gianatti A; L'Imperio V; Morbini P; Pagni F
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466794
[TBL] [Abstract][Full Text] [Related]
2. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study.
Guerini Rocco E; Eccher A; Girolami I; Graziano P; Fontanini G; Vigliar E; Troncone G; Barberis M; Morbini P; Martini M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204568
[TBL] [Abstract][Full Text] [Related]
3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
Gangadhar P; Ilanthodi S; Shetty R; Shenoy KK; Philipose TR
J Oral Maxillofac Pathol; 2024; 28(1):29-36. PubMed ID: 38800420
[TBL] [Abstract][Full Text] [Related]
5. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
Nuti S; Zhang Y; Zerrouki N; Roach C; Bänfer G; Kumar GL; Manna E; Diezko R; Kersch K; Rüschoff J; Jasani B
Histopathology; 2022 Dec; 81(6):732-741. PubMed ID: 35993150
[TBL] [Abstract][Full Text] [Related]
6. Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications.
Deuss E; Kürten C; Fehr L; Kahl L; Zimmer S; Künzel J; Stauber RH; Lang S; Hussain T; Brandau S
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893222
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study.
Lu H; Kuang D; Zhou P; Zeng J; Xia Q; Wang J; Duan P; Jiang L; Zang S; Jin Y; Jiang X; Li J; Tang W; Zhou J; Chen J; Ying J
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37968103
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
11. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
12. Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma.
Ribbat-Idel J; Dressler FF; Krupar R; Watermann C; Paulsen FO; Kuppler P; Klapper L; Offermann A; Wollenberg B; Rades D; Laban S; Reischl M; Bruchhage KL; Idel C; Perner S
Front Med (Lausanne); 2021; 8():640515. PubMed ID: 33987192
[No Abstract] [Full Text] [Related]
13. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
14. Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Puladi B; Ooms M; Kintsler S; Houschyar KS; Steib F; Modabber A; Hölzle F; Knüchel-Clarke R; Braunschweig T
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503218
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
16. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
17. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Oweida A; Lennon S; Calame D; Korpela S; Bhatia S; Sharma J; Graham C; Binder D; Serkova N; Raben D; Heasley L; Clambey E; Nemenoff R; Karam SD
Oncoimmunology; 2017; 6(10):e1356153. PubMed ID: 29123967
[TBL] [Abstract][Full Text] [Related]
18. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
19. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
20. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
